NKMax America, a biotechnology company harnessing the power of the body’s immune system through the development of Natural Killer (NK) cell therapies, announced that it has treated the first subject in study SNK01-MX03, a phase I clinical trial evaluating SNK, an ex vivo expanded autologous natural killer cell therapeutic, in patients with plaque psoriasis.
August 20, 2019
· 1 min read